



Pathogenesis and Novel Therapies of Acute Leukemias

Guest Editors:

Dr. Gwen Nichols

Chief Medical Officer, The
Leukemia & Lymphoma Society
(LLS), Rye Brook, NY, USA

Dr. Alexandra Stevens

Department of Pediatrics,
Section of Pediatric
Hematology/Oncology, Texas
Children's Hospital, Houston, TX,
USA

Deadline for manuscript
submissions:
closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

Prevention and early detection have greatly reduced age-adjusted death rates in many types of cancer. Much of the progress in acute leukemia has come from improvements in classification, monitoring and modified treatment regimens.

How can we leverage recent discoveries that have identified mutations in genes that can lead to leukemia well before leukemia occurs, or genes that are major drivers of leukemia when it occurs? Can this knowledge be used to identify individuals at risk of developing leukemia, enabling us to create diagnostic and therapeutic strategies that will prevent leukemia? Will improved subclassification of leukemia at the molecular level help novel, more targeted therapies for these diseases be successful?

This Special Issue will explore what we are learning about leukemia pathogenesis, and present progress towards new treatments that can replace “one size fits all” therapy for acute leukemia.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI